STOCK TITAN

BioLargo Validates Key Performance Metrics of Its Cellinity Battery Energy Storage Technology

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BioLargo, Inc. (OTCQX:BLGO) has announced successful preliminary internal testing of its Cellinity battery technology, confirming key performance metrics. The tests verified the stability of the battery cell chemistry, reliability of the sealed, non-venting cell design, and its ability to quickly charge and discharge at high voltage. Cellinity is positioned as a superior alternative to lithium-ion batteries for long-duration energy storage applications, offering advantages in safety, sustainability, longevity, and energy density.

The company is now proceeding with third-party validation testing at acclaimed facilities to further assess Cellinity's electrochemical performance. BioLargo is also advancing the development of larger format 'Spartan' Cellinity cells and battery modules. The announcement highlights the significant market potential for energy storage solutions, with global supply projected to reach over 5 terawatts by 2050 and market value estimates between $1-3 trillion by 2040.

BioLargo, Inc. (OTCQX:BLGO) ha annunciato il successo di test preliminari interni sulla sua tecnologia delle batterie Cellinity, confermando i principali indicatori di prestazione. I test hanno verificato la stabilità della chimica delle celle della batteria, l'affidabilità del design delle celle sigillate e non ventilate e la capacità di caricare e scaricare rapidamente ad alta tensione. Cellinity è posizionata come un'alternativa superiore alle batterie al litio-ione per applicazioni di stoccaggio energetico a lungo termine, offrendo vantaggi in termini di sicurezza, sostenibilità, longevità e densità energetica.

L'azienda sta ora procedendo con test di convalida da parte di terzi presso strutture rinomate per valutare ulteriormente le prestazioni elettrochimiche di Cellinity. BioLargo sta anche avanzando nello sviluppo di celle e moduli di batteria 'Spartan' di formato maggiore. L'annuncio evidenzia il significativo potenziale di mercato per le soluzioni di stoccaggio energetico, con una fornitura globale prevista di oltre 5 terawatt entro il 2050 e stime del valore di mercato comprese tra 1 e 3 trilioni di dollari entro il 2040.

BioLargo, Inc. (OTCQX:BLGO) ha anunciado el éxito de las pruebas internas preliminares de su tecnología de baterías Cellinity, confirmando los principales indicadores de rendimiento. Las pruebas verificaron la estabilidad de la química de la celda de la batería, la fiabilidad del diseño de la celda sellada y no ventilada y su capacidad para cargar y descargar rápidamente a alta tensión. Cellinity se posiciona como una alternativa superior a las baterías de litio-ion para aplicaciones de almacenamiento de energía a largo plazo, ofreciendo ventajas en términos de seguridad, sostenibilidad, longevidad y densidad energética.

La empresa ahora está avanzando con pruebas de validación por parte de terceros en instalaciones acreditadas para evaluar aún más el rendimiento electroquímico de Cellinity. BioLargo también está desarrollando celdas y módulos de batería 'Spartan' de mayor formato. El anuncio destaca el significativo potencial de mercado para soluciones de almacenamiento de energía, con una proyección de suministro global que alcanzará más de 5 teravatios para 2050 y estimaciones de valor de mercado entre 1 y 3 billones de dólares para 2040.

BioLargo, Inc. (OTCQX:BLGO)는 Cellinity 배터리 기술의 성공적인 초기 내부 테스트를 발표하며 주요 성능 지표를 확인했습니다. 테스트는 배터리 셀 화학의 안정성, 밀폐형 비환기 셀 디자인의 신뢰성고전압에서 신속하게 충전 및 방전할 수 있는 능력을 검증했습니다. Cellinity는 장기간 에너지 저장 애플리케이션을 위한 리튬 이온 배터리에 대한 우수한 대안으로 자리 잡고 있으며, 안전성, 지속 가능성, 긴 수명 및 에너지 밀도 면에서 장점을 제공합니다.

회사는 Cellinity의 전기화학적 성능을 더욱 평가하기 위해 저명한 시설에서 제3자 검증 테스트를 진행하고 있습니다. BioLargo는 또한 '스파르탄' Cellinity 셀 및 배터리 모듈의 대형 포맷 개발을 진행하고 있습니다. 이 발표는 2050년까지 전 세계 공급이 5테라와트 이상에 이를 것으로 예상되는 에너지 저장 솔루션상당한 시장 잠재력을 강조하고 있으며, 2040년까지 시장 가치 전망이 1조에서 3조 달러 사이로 추정됩니다.

BioLargo, Inc. (OTCQX:BLGO) a annoncé le succès de tests internes préliminaires de sa technologie de batterie Cellinity, confirmant les principaux paramètres de performance. Les tests ont vérifié la stabilité de la chimie des cellules de batterie, la fiabilité du design des cellules scellées et non ventilées, ainsi que sa capacité à charger et décharger rapidement à haute tension. Cellinity est positionnée comme une alternative supérieure aux batteries lithium-ion pour les applications de stockage d'énergie à long terme, offrant des avantages en termes de sécurité, de durabilité, de longévité et de densité énergétique.

L'entreprise procède maintenant à des tests de validation par des tiers dans des installations renommées pour évaluer davantage les performances électrochimiques de Cellinity. BioLargo avance également le développement de cellules et de modules de batterie de plus grand format 'Spartan'. L'annonce met en évidence le potentiel de marché considérable pour les solutions de stockage d'énergie, avec une offre globale projetée à plus de 5 térawatts d'ici 2050 et des estimations de valeur de marché entre 1 et 3 billions de dollars d'ici 2040.

BioLargo, Inc. (OTCQX:BLGO) hat den Erfolg von vorläufigen internen Tests seiner Cellinity-Batterietechnologie bekannt gegeben und die wichtigsten Leistungskennzahlen bestätigt. Die Tests haben die Stabilität der Batteriezellchemie, die Zuverlässigkeit des versiegelten, nicht belüfteten Zellendesigns und die Fähigkeit, bei hoher Spannung schnell zu laden und zu entladen überprüft. Cellinity positioniert sich als überlegene Alternative zu Lithium-Ionen-Batterien für langfristige Energiespeicheranwendungen und bietet Vorteile in Bezug auf Sicherheit, Nachhaltigkeit, Langlebigkeit und Energiedichte.

Das Unternehmen geht nun mit drittanbietervalidierten Tests in angesehenen Einrichtungen weiter, um die elektrochemische Leistung von Cellinity weiter zu bewerten. BioLargo fördert auch die Entwicklung von größeren „Spartan“ Cellinity-Zellen und Batteriemodulen. Die Ankündigung hebt das signifikante Marktpotenzial für Energiespeicherlösungen hervor, da die weltweite Versorgung voraussichtlich bis 2050 über 5 Terawatt erreichen wird und der Marktwert bis 2040 auf 1-3 Billionen Dollar geschätzt wird.

Positive
  • Successful internal testing confirming key performance metrics of Cellinity battery technology
  • Verified stability of battery cell chemistry and reliability of sealed, non-venting cell design
  • Demonstrated ability for quick charging and discharging at high voltage
  • Advancing to third-party validation testing at acclaimed facilities
  • Development of larger format 'Spartan' Cellinity cells and battery modules underway
  • Potential to capitalize on a rapidly growing energy storage market projected to be worth $1-3 trillion by 2040
Negative
  • None.

WESTMINSTER, CA / ACCESSWIRE / October 14, 2024 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary BioLargo Energy Technologies, Inc. completed preliminary internal testing of its prototype battery cells confirming many of the technology's exceptional performance claims that make it an attractive battery technology for long duration energy storage.

Cellinity's Advantages
Cellinity's Advantages
Advantages of BioLargo's Cellinity Battery Technology over lithium-ion

The tests, done to verify the battery's performance claims made by its original inventors, confirmed the stability of the chemistry of the battery cell and the reliability of the component construction as a sealed, non-venting cell design with no self-discharging. The tests also helped verify the battery's ability to quickly charge and discharge at a high voltage.

Cellinity™ is BioLargo's next-generation battery platform designed to provide a better alternative to lithium-ion technology for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is safer, more sustainable, longer lasting, and more energy-dense than lithium-ion batteries, traits that make it ideal for large-format long-duration energy storage applications. Learn more about Cellinity at www.BioLargoEnergy.com.

In addition to these internal tests, the company is also organizing third-party validation testing to be done on the more complex aspects of Cellinity's electrochemical performance with at least two acclaimed testing facilities.

Dennis P. Calvert, President and CEO of BioLargo, commented "With these results in hand, our engineers are now advancing the next steps in Cellinity's development: design and production of the larger format 'Spartan' Cellinity cells, and design and production of battery modules containing those cells. Stay tuned - we're very excited about the future of this important battery technology, and we think you should be too."

He continued, "According to a recently published article in The Economist titled 'Clean energy's next trillion-dollar business', global energy storage experts have predicted the global supply of battery energy storage will need to increase from today's 200 gigawatts to more than a terawatt by 2030 and more than five terawatts by 2050, fueling a market projected to be worth between $200 billion and $700 billion by 2030 and between $1 and $3 trillion by 2040. These projections underscore the critical role of batteries in the global energy transition and the massive global investment in battery innovation required to meet those targets. Because of its unique differentiators in safety, energy density, and lifespan, Cellinity is especially well-suited to assist in the global energy transition, and we intend to capitalize on that."

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Contact Information

Dennis Calvert
President and CEO
dennis.calvert@biolargo.com
(888) 400-2863

SOURCE: BioLargo, Inc.



View the original press release on accesswire.com

FAQ

What are the key advantages of BioLargo's Cellinity battery technology over lithium-ion batteries?

Cellinity offers advantages in safety, sustainability, longevity, and energy density compared to lithium-ion batteries. It is designed for long-duration energy storage applications, making it suitable for grid-scale storage, renewable energy storage, and electric vehicle charging stations.

What were the results of BioLargo's internal testing of Cellinity battery cells?

The internal testing confirmed the stability of the battery cell chemistry, reliability of the sealed, non-venting cell design, and the ability to quickly charge and discharge at high voltage. These results validate many of the exceptional performance claims of the Cellinity technology.

What are BioLargo's next steps in developing the Cellinity battery technology?

BioLargo is organizing third-party validation testing at acclaimed facilities to assess Cellinity's electrochemical performance. The company is also advancing the design and production of larger format 'Spartan' Cellinity cells and battery modules containing those cells.

What is the projected market size for battery energy storage according to BioLargo's press release?

According to the press release, the global battery energy storage market is projected to be worth between $200 billion and $700 billion by 2030, and between $1 and $3 trillion by 2040. The global supply of battery energy storage is expected to increase from 200 gigawatts today to more than 5 terawatts by 2050.

BIOLARGO INC

OTC:BLGO

BLGO Rankings

BLGO Latest News

BLGO Stock Data

72.15M
258.54M
14.01%
0.04%
Chemicals
Basic Materials
Link
United States of America
Westminster